Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study.
3-Hydroxybutyric Acid
/ blood
Adult
Analysis of Variance
Anthropometry
Aryldialkylphosphatase
/ blood
Body Mass Index
C-Reactive Protein
/ analysis
Cardiotonic Agents
/ administration & dosage
Cardiovascular Diseases
/ etiology
Catechin
/ administration & dosage
Dietary Supplements
Female
Heart Disease Risk Factors
Humans
Ketone Bodies
/ blood
Male
Middle Aged
Multiple Sclerosis
/ blood
Pilot Projects
Serum Albumin
/ analysis
Treatment Outcome
Waist-Height Ratio
cardiac risk
epigallocatechin gallate
ketone bodies
multiple sclerosis
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
received:
04
11
2020
revised:
04
12
2020
accepted:
07
12
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
22
4
2021
Statut:
epublish
Résumé
Multiple sclerosis (MS) is a neurodegenerative disease that causes anthropometric changes characterised by functional disability, increase in fat mass, and decrease in lean mass. All these variables are related to a greater cardiac risk. The polyphenol epigallocatechin gallate (EGCG) and an increase in ketone bodies in the blood have been shown to have beneficial effects on anthropometric and biochemical variables related to cardiovascular activity. The aim of this study was to analyse the impact of the intervention with EGCG and ketone bodies on cardiac risk in MS patients. A population of 51 MS patients were randomly assigned to a control group and an intervention group (daily dose of 800 mg of EGCG and 60 mL of coconut oil). Both groups followed an isocaloric diet for 4 months. Levels of beta-hydroxybutyrate (BHB), albumin, paraoxonase 1 (PON1) and C-reactive protein (CRP) were measured in serum before and after the intervention, as well as determining functional ability, waist circumference, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), fat percentage and muscle percentage. After 4 months, in the intervention group there was a significant increase in BHB, PON1 and albumin, while CRP did not vary; a significant decrease in cardiac risk associated with a significant decline in WHR; as well as a significant increase in muscle percentage. By contrast, these changes were not observed in the control group. Finally, results from analysis of variance (ANOVA) revealed a significant time-condition interaction effect, observing that WHtR and fat mass decreased in the intervention group, while they increased in the control group.
Identifiants
pubmed: 33322022
pii: nu12123792
doi: 10.3390/nu12123792
pmc: PMC7763038
pii:
doi:
Substances chimiques
Cardiotonic Agents
0
Ketone Bodies
0
Serum Albumin
0
Catechin
8R1V1STN48
C-Reactive Protein
9007-41-4
epigallocatechin gallate
BQM438CTEL
Aryldialkylphosphatase
EC 3.1.8.1
PON1 protein, human
EC 3.1.8.1
3-Hydroxybutyric Acid
TZP1275679
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Références
J Nutr Biochem. 2014 Jan;25(1):1-18
pubmed: 24314860
Food Funct. 2013 Sep;4(9):1402-9
pubmed: 23892389
Obes Rev. 2015 Jan;16(1):64-76
pubmed: 25402637
Am J Clin Nutr. 2007 Nov;86(5):1539-47
pubmed: 17991670
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
Eur J Intern Med. 2018 Jun;52:8-12
pubmed: 29680174
Curr Nutr Rep. 2018 Sep;7(3):97-106
pubmed: 30128963
Cancer Prev Res (Phila). 2012 Mar;5(3):393-402
pubmed: 22246619
Eur J Clin Invest. 2012 May;42(5):487-95
pubmed: 21955281
Medicine (Baltimore). 2018 Jul;97(30):e11639
pubmed: 30045310
Antioxidants (Basel). 2019 Jun 06;8(6):
pubmed: 31174371
Ann Nutr Metab. 2009;54(2):151-7
pubmed: 19390166
Eur Heart J. 2010 Mar;31(6):737-46
pubmed: 19933515
Int J Cardiol. 2014 Oct 20;176(3):951-5
pubmed: 25192782
Acta Neurol Belg. 2020 Aug;120(4):853-861
pubmed: 30182258
PLoS One. 2012;7(5):e35476
pubmed: 22567104
Life Sci. 2013 Sep 3;93(8):307-12
pubmed: 23871988
Int J Obes (Lond). 2005 Jan;29(1):78-84
pubmed: 15520830
J Clin Invest. 1995 Dec;96(6):2882-91
pubmed: 8675659
Curr Drug Metab. 2006 Oct;7(7):755-809
pubmed: 17073579
Front Physiol. 2020 Feb 06;11:63
pubmed: 32116773
JAMA. 2012 Jun 27;307(24):2627-34
pubmed: 22735432
J Clin Lipidol. 2020 Jan - Feb;14(1):143-153
pubmed: 32061531
Neurol Res. 2012 Oct;34(8):754-60
pubmed: 22971465
Mol Neurobiol. 2017 May;54(4):2961-2968
pubmed: 27026183
Eur J Clin Nutr. 2010 Jan;64(1):16-22
pubmed: 19654593
Int J Biochem Cell Biol. 2016 Dec;81(Pt B):356-363
pubmed: 27312742
Luminescence. 2016 Dec;31(8):1474-1478
pubmed: 27062681
Biochem Biophys Res Commun. 2008 Sep 12;374(1):55-9
pubmed: 18611391
Noro Psikiyatr Ars. 2018;55(Suppl 1):S66-S68
pubmed: 30692860
J Ethnopharmacol. 2018 Jan 10;210:296-310
pubmed: 28864169
PLoS One. 2014 Sep 29;9(9):e108158
pubmed: 25264868
Braz J Phys Ther. 2016 Oct 27;20(6):592-600
pubmed: 27849287
Mult Scler Relat Disord. 2018 Oct;25:1-4
pubmed: 30014875
Nutr Res Rev. 2010 Dec;23(2):247-69
pubmed: 20819243
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Am J Clin Nutr. 2010 Jan;91(1):280S-283S
pubmed: 19923373
Biomolecules. 2019 Nov 05;9(11):
pubmed: 31694323
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Neurol Neurosurg Psychiatry. 2017 May;88(5):395-401
pubmed: 28320766
Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):473-482
pubmed: 31852221
Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):82-90
pubmed: 29544976
J Nutr Biochem. 2019 Dec;74:108225
pubmed: 31629963
Redox Rep. 2014 Mar;19(2):49-58
pubmed: 24225313
Am J Clin Nutr. 2007 Aug;86(2):276-84
pubmed: 17684196
Naunyn Schmiedebergs Arch Pharmacol. 2016 Nov;389(11):1225-1234
pubmed: 27492718
Am J Clin Nutr. 2005 Sep;82(3):531-7
pubmed: 16155264
Evid Based Complement Alternat Med. 2012;2012:163106
pubmed: 22919410
Handb Clin Neurol. 2014;122:15-58
pubmed: 24507512
Physiol Behav. 2008 May 23;94(2):300-7
pubmed: 18282589
Amino Acids. 2016 Jun;48(6):1477-89
pubmed: 26969256
Mol Nutr Food Res. 2009 Jun;53(6):709-15
pubmed: 19437485
Lancet. 2005 Nov 5;366(9497):1640-9
pubmed: 16271645
Am J Pathol. 2012 Jan;180(1):221-34
pubmed: 22056360
J Nutr. 2018 Oct 1;148(10):1556-1563
pubmed: 30204921
Oxid Med Cell Longev. 2018 Aug 9;2018:1603872
pubmed: 30159110
Br J Nutr. 2009 Mar;101(6):886-94
pubmed: 18710606
J Obes. 2018 Nov 1;2018:8370304
pubmed: 30515323
Dis Markers. 2013;34(5):341-8
pubmed: 23478275
Medicine (Baltimore). 2019 Feb;98(7):e14469
pubmed: 30762765
BMC Vet Res. 2014 Mar 25;10:74
pubmed: 24666514
Mol Aspects Med. 2012 Feb;33(1):107-18
pubmed: 22020144
Cardiol Res Pract. 2020 Mar 16;2020:4250793
pubmed: 32257425
J Am Coll Nutr. 2007 Aug;26(4):396S-402S
pubmed: 17906193
Front Immunol. 2018 Mar 14;9:457
pubmed: 29593720
Adv Exp Med Biol. 2010;660:153-66
pubmed: 20221878
Mult Scler. 2009 Mar;15(3):399-402
pubmed: 18845659
PLoS One. 2015 Oct 20;10(10):e0139817
pubmed: 26485706